It did not take long. In the midst of the pricing debacle created by Mylan and the EpiPen, one bold CEO has stepped forward. Brent Saunders, Allergan’s leader, has taken a clear stand. Writing on his CEO blog, Saunders tackles the elephant in the room.[1] According to Saunders, “those who have taken aggressive or predatory price increases have violated [the] social contract.” That social contract is between the pharmaceutical…
The post Pharma Pricing & One Bold CEO appeared first on Whitelaw Compliance Group, LLC.
